LOADING

Products

PACLINAB

Generic Name: Paclitaxel albumin bound
Originator’s name: Abraxane®
Paclinab is a microtubule inhibitor indicated for the treatment of patients with Metastatic breast cancer, locally advanced or metastatic non-small cell lung cancer, Metastatic adenocarcinoma of pancreas. It is recommended by guidelines such as NCCN and ESMO as first line regimens in metastatic pancreatic cancer in combination with gemcitabine and in nonsmall cell lung cancer in combination with carboplatin.

INDICATION 

  • Metastatic Breast Cancer: Paclinab is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated.
  • Non-Small Cell Lung Cancer: Paclinab is indicated for the first-line treatment of locally advanced or metastatic non-small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.
  • Adenocarcinoma of the Pancreas: Paclinab is indicated for the first-line treatment of patients with metastatic adenocarcinoma of the pancreas, in combination with gemcitabine.

PALBOCAP

Generic Name: Palbociclib
Originator’s name: Ibrance®
Palbociclib is the first FDA-approved medication in a class of therapy called CDK 4/6 inhibitors. Taken in combination with certain hormonal therapies, Palbocap works to put the brakes on cell growth and division in hormone receptor positive, HER2- metastatic breast

INDICATION
Palbocap is a prescription medicine used to treat hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)- negative breast cancer that has spread to other parts of the body (metastatic) in combination with:

  • An aromatase inhibitor as the first hormonal based therapy in women who have gone through menopause.
  • Fulvestrant in women with disease progression following hormonal therapy

PRALATREXATE

Generic Name: Pralatrexate
Originator’s name: Folotyn®
Pralatrexate is a folate analogue metabolic inhibitor indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This indication is based on overall response rate. Clinical benefit such as improvement in progression free survival or overall survival has not been demonstrated.

INDICATION
Treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This indication is based on overall response rate.

EXOPIO

Generic Name: Naltrexone (extended release)
Originator’s name: Vivitrol®
Exopio is an opioid receptor antagonist with highest affinity for the mu opioid receptor. Naltrexone has little or no opioid agonist activity. Treatment with Exopio should be part of a comprehensive management program that includes psychosocial support.

INDICATION

  •  Opioid Dependence
  • Alcohol Dependence

PADYNEX

Generic Name: Trastuzumab Emtansine
Originator’s name: Kadcyla®
Padynex is a HER2 antibody drug conjugate. The antibody portion is Trastuzumab, which is humanized anti-HER2 IgG1, and produced in the mammalian Chinese Hamster Ovary cells. The drug portion is DM1, which is a maytansine derivative that inhibits microtubules. These two portions are covalently connected by 4-[N-maleimidomethyl] cyclohexane-1-carboxylate (MCC), which is a stable thioether linker. Together MCC and DM1 are called Emtansine and are produced by chemical synthesis. Trastuzumab Emtansine binds to the HER2 receptor’s sub-domain IV and goes into the cell by receptormediated endocytosis. Lysosomes degrade Trastuzumab Emtansine and release
DM1. DM1 binds to tubulin in microtubules and inhibits microtubule function producing cell arrest and apoptosis. As well, similar to Trastuzumab, in vitro studies have shown that both HER2 receptor signalling inhibition and antibodydependent cytotoxicity are mediated by Trastuzumab Emtansine 

INDICATION

  • Monotherapy for the treatment of HER2- positive, unresectable, locally advanced or metastatic breast cancer, in adult patients who have previously received trastuzumab and a taxane separately or in combination (initiated by a specialist)
  • Monotherapy for the treatment of HER2- positive, unresectable, locally advanced or metastatic breast cancer, in adult patients who have developed disease recurrence during or within 6 months of completing adjuvant therapy (initiated by a specialist)

TRIENTINE

Generic Name: Trientine
Originator’s name: Syprine®
Trientine hydrochloride is a chelating compound for removal of excess copper from the body. It is used for the treatment of Wilson’s disease which is genetic metabolic defect

INDICATION

  • Wilson’s disease in patients intolerant of
    penicillamine.